Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 1
2006 1
2007 6
2008 5
2009 1
2010 3
2011 1
2012 3
2013 6
2014 8
2015 7
2016 5
2017 6
2018 8
2019 7
2020 8
2021 6
2022 7
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.
Xu Q, Streuer A, Jann JC, Altrock E, Schmitt N, Flach J, Sens-Albert C, Rapp F, Wolf J, Nowak V, Weimer N, Obländer J, Palme I, Kuzina M, Jawhar A, Darwich A, Weis CA, Marx A, Wuchter P, Costina V, Jäger E, Sperk E, Neumaier M, Fabarius A, Metzgeroth G, Nolte F, Steiner L, Levkin PA, Jawhar M, Hofmann WK, Riabov V, Nowak D. Xu Q, et al. Among authors: fabarius a. Nat Commun. 2023 Mar 17;14(1):1497. doi: 10.1038/s41467-023-37175-8. Nat Commun. 2023. PMID: 36932114 Free PMC article.
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Isfort S, Manz K, Teichmann LL, Crysandt M, Burchert A, Hochhaus A, Saussele S, Kiani A, Göthert JR, Illmer T, Schafhausen P, Al-Ali HK, Stegelmann F, Hänel M, Pfeiffer T, Giagounidis A, Franke GN, Koschmieder S, Fabarius A, Ernst T, Warnken-Uhlich M, Wolber U, Kohn D, Pfirrmann M, Wolf D, Brümmendorf TH; German CML study group. Isfort S, et al. Among authors: fabarius a. Ann Hematol. 2023 Oct;102(10):2741-2752. doi: 10.1007/s00277-023-05394-0. Epub 2023 Aug 18. Ann Hematol. 2023. PMID: 37592092 Free PMC article. Clinical Trial.
The chromosomal basis of cancer.
Duesberg P, Li R, Fabarius A, Hehlmann R. Duesberg P, et al. Among authors: fabarius a. Cell Oncol. 2005;27(5-6):293-318. doi: 10.1155/2005/951598. Cell Oncol. 2005. PMID: 16373963 Free PMC article. Review.
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.
Metzgeroth G, Steiner L, Naumann N, Lübke J, Kreil S, Fabarius A, Haferlach C, Haferlach T, Hofmann WK, Cross NCP, Schwaab J, Reiter A. Metzgeroth G, et al. Among authors: fabarius a. Leukemia. 2023 Sep;37(9):1860-1867. doi: 10.1038/s41375-023-01958-1. Epub 2023 Jul 15. Leukemia. 2023. PMID: 37454239 Free PMC article.
Aneuploidy and cancer: from correlation to causation.
Duesberg P, Li R, Fabarius A, Hehlmann R. Duesberg P, et al. Among authors: fabarius a. Contrib Microbiol. 2006;13:16-44. doi: 10.1159/000092963. Contrib Microbiol. 2006. PMID: 16627957 Review.
Impact of emerging ACA on survival in chronic myeloid leukemia (CML).
Hehlmann R, Lauseker M, Voskanyan A, Fabarius A, Haferlach C, Hochhaus A, Saußele S. Hehlmann R, et al. Among authors: fabarius a. Leukemia. 2022 Oct;36(10):2544-2547. doi: 10.1038/s41375-022-01681-3. Epub 2022 Aug 23. Leukemia. 2022. PMID: 35999258 Free PMC article. No abstract available.
Cancer drug resistance: the central role of the karyotype.
Duesberg P, Li R, Sachs R, Fabarius A, Upender MB, Hehlmann R. Duesberg P, et al. Among authors: fabarius a. Drug Resist Updat. 2007 Feb-Apr;10(1-2):51-8. doi: 10.1016/j.drup.2007.02.003. Epub 2007 Mar 26. Drug Resist Updat. 2007. PMID: 17387035 Review.
94 results